Dec 29, 2025 | Press Releases
CULVER CITY, Calif., December 29, 2025 – ImmunityBio, Inc. (NASDAQ: IBRX), a commercial-stage immunotherapy company, today announced that OncoDaily has recognized Dr. Patrick Soon-Shiong as being one of “The 100 Most Influential People in Oncology in 2025.”...
Dec 16, 2025 | Press Releases
Results from the QUILT-3.032 study of 80 subjects, published in The Journal of Urology, showed 96% disease-specific survival and 83% progression-free survival at 36 months, demonstrating the long-term duration of effect of ANKTIVA® in patients with high-grade...
Dec 12, 2025 | Press Releases
ANKTIVA plus BCG is the first immunotherapy for non-muscle invasive bladder cancer (NMIBC) with carcinoma in situ (CIS), with or without papillary tumors, to receive a positive recommendation for marketing authorization in Europe. For patients whose disease does not...
Nov 13, 2025 | Press Releases
Insights show patients with non-muscle invasive bladder cancer want to explore new treatment options, yet fewer than one in five say their doctors discuss all available procedures/treatments at most or every visit Nearly three in four patients said they would choose...
Nov 5, 2025 | Press Releases
Q3 2025 Revenue and Other Income Growth with Continued Strong Sales Momentum: $33.7 million of total revenue and other income, up from $26.4 million in Q2 2025. Product Revenue: Up 434% in Q3 2025 versus Q3 2024, with year-to-date sales of $74.7 million. ANKTIVA® Unit...
Sep 8, 2025 | Press Releases
Severe lymphopenia, an adverse treatment effect associated with chemotherapy, radiotherapy, and immunotherapy, significantly lowers overall survival in non-small cell lung cancer and multiple types of cancer.1,2 With ANKTIVA, the first FDA-approved...
